Treatment of Sporotrichosis

Introduction to Treatment Guidelines

The Infectious Diseases Society of America recommends that voriconazole should not be used for the treatment of sporotrichosis due to its inferior antifungal activity against Sporothrix schenckii compared to itraconazole 1, 2, 3

The Infectious Diseases Society of America recommends itraconazole 200 mg orally daily for 3-6 months as the first-line treatment for cutaneous and lymphocutaneous sporotrichosis, with success rates of 90-100% 1, 2
For severe or disseminated disease, the Infectious Diseases Society of America recommends amphotericin B (lipid formulation 3-5 mg/kg daily) as the initial treatment, followed by itraconazole 200 mg twice daily to complete at least 12 months of total therapy 1, 2, 3
For immunocompromised patients, the Infectious Diseases Society of America recommends lifelong suppressive therapy with itraconazole 200 mg daily to prevent relapse 1, 2, 4

The Infectious Diseases Society of America recommends checking serum itraconazole levels after 2 weeks of therapy to ensure adequate drug exposure 1, 2, 3
The Infectious Diseases Society of America advises taking itraconazole capsules with food to enhance absorption, and avoiding concomitant use of proton pump inhibitors, H2 blockers, phenytoin, or rifampicin, as these significantly decrease itraconazole efficacy 5

The Infectious Diseases Society of America states that fluconazole and ketoconazole are inferior to itraconazole for sporotrichosis treatment, and fluconazole should only be reserved for patients who cannot tolerate itraconazole, requiring high doses (minimum 400-800 mg daily) with lower success rates 1, 6, 7

The patient may have levels below the therapeutic threshold needed to suppress Sporothrix schenckii, as reported in a study published in 2007 8
Gastrointestinal conditions affecting absorption can lead to treatment failure despite appropriate dosing, according to a study published in Clinical Infectious Diseases in 2007 8
For severe or osteoarticular disease, a dose of 200 mg twice daily for at least 12 months is required, as recommended by the Infectious Diseases Society of America, based on a study published in Clinical Infectious Diseases in 2007 8
Premature discontinuation or underdosing leads to relapse, as noted in a study published in Clinical Infectious Diseases in 2007 8

If itraconazole levels are subtherapeutic, the dose should be increased to 200 mg twice daily, as suggested by a study published in Clinical Infectious Diseases in 2007 8
If itraconazole levels are therapeutic but disease persists, amphotericin B therapy should be resumed, according to a study published in Clinical Infectious Diseases in 2007 8
If levels are therapeutic but disease persists, continue amphotericin B therapy until clinical improvement, then retry itraconazole at a higher dose, as recommended by a study published in Clinical Infectious Diseases in 2007 8

Never assume adequate itraconazole exposure without measuring serum levels, as emphasized by a study published in Clinical Infectious Diseases in 2007 8
Do not discontinue therapy prematurely; cutaneous sporotrichosis requires 3-6 months minimum, osteoarticular disease requires ≥12 months, as noted in a study published in Clinical Infectious Diseases in 2007 8